PAOG To Extend CBD Nutraceuticals Reach Into $3.8 Billion Market
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
- Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
- RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
- PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
- The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.